Matrix metalloproteinases and descending aortic aneurysms: Parity, disparity, and switch

Journal of Cardiac Surgery

Volumn 27, Issue 1, 2012, Pages 81-90

  Theruvath, Tom P ^a,b   Jones, Jeffrey A ^a,b   Ikonomidis, John S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; MATRIX METALLOPROTEINASE; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ABDOMINAL AORTA ANEURYSM; CARDIOVASCULAR DISEASE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; HUMAN; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; REVIEW; STOICHIOMETRY; THORACIC AORTA ANEURYSM;

AORTA, ABDOMINAL; AORTA, THORACIC; AORTIC ANEURYSM, ABDOMINAL; AORTIC ANEURYSM, THORACIC; HUMANS; MATRIX METALLOPROTEINASES;

EID: 84863421409     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2011.01315.x     Document Type: Review

References (96)

1. Bickerstaff LK, Pairolero PC, Hollier LH, et al: Thoracic aortic aneurysms: A population-based study. Surgery 1982; 92: 1103-1108. (Pubitemid 13083932)
2. Clouse WD, Hallett JW, Jr., Schaff HV, et al,: Improved prognosis of thoracic aortic aneurysms: A population-based study. JAMA 1998; 280: 1926-1929. (Pubitemid 28559810)
3. Lakatta EG, Levy D,: Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part I: Aging arteries: A "set up" for vascular disease. Circulation 2003; 107: 139-146. (Pubitemid 36070946)
4. Howden LM, Meyer JA,: Age and Sex Composition: 2010. 2010 Census Briefs. U.S. Census Bureau, 2011, pp. 1-15.
5. Olsson C, Thelin S, Stahle E, et al,: Thoracic aortic aneurysm and dissection: Increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006; 114: 2611-2618. (Pubitemid 44967344)
6. Barbour JR, Spinale FG, Ikonomidis JS,: Proteinase systems and thoracic aortic aneurysm progression. J Surg Res 2007; 139: 292-307. (Pubitemid 46551165)
7. Elefteriades JA,: Natural history of thoracic aortic aneurysms: Indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002; 74: S1877-S1880; discussion S92-98. (Pubitemid 35222723)
8. Jones JA, Beck C, Barbour JR, et al: Alterations in aortic cellular constituents during thoracic aortic aneurysm development: Myofibroblast-mediated vascular remodeling. Am J Pathol 2009; 175: 1746-1756.
9. Thompson RW, Parks WC,: Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 1996; 800: 157-174. (Pubitemid 27028953)
10. Ruddy JM, Jones JA, Spinale FG, et al,: Regional heterogeneity within the aorta: Relevance to aneurysm disease. J Thorac Cardiovasc Surg 2008; 136: 1123-1130.
11. Jones JA, Barbour JR, Stroud RE, et al: Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res 2008; 45: 457-468.
12. Jones JA, Ruddy JM, Bouges S, et al: Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol 2010; 299: H114-H124.
13. Keeling WB, Armstrong PA, Stone PA, et al,: An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. Vasc Endovascular Surg 2005; 39: 457-464. (Pubitemid 41790136)
14. Galis ZS, Khatri JJ,: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002; 90: 251-262. (Pubitemid 34633925)
15. Ferrans VJ,: New insights into the world of matrix metalloproteinases. Circulation 2002; 105: 405-407. (Pubitemid 34141692)
16. Zervoudaki A, Economou E, Stefanadis C, et al: Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119-124. (Pubitemid 36292367)
17. Aimes RT, Quigley JP,: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995; 270: 5872-5876.
18. Goodall S, Porter KE, Bell PR, et al,: Enhanced invasive properties exhibited by smooth muscle cells are associated with elevated production of MMP-2 in patients with aortic aneurysms. Eur J Vasc Endovasc Surg 2002; 24: 72-80. (Pubitemid 41079391)
19. Goodall S, Crowther M, Hemingway DM, et al,: Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001; 104: 304-309. (Pubitemid 32666952)
20. Longo GM, Xiong W, Greiner TC, et al,: Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-632. (Pubitemid 34988786)
21. Jones JA, Barbour JR, Lowry AS, et al: Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysm. J Vasc Surg 2006; 44: 1314-1321. (Pubitemid 44828394)
22. Ikonomidis JS, Barbour JR, Amani Z, et al: Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 2005; 112: I242-I248. (Pubitemid 41266681)
23. Xiong W, Knispel R, MacTaggart J, et al,: Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J Biol Chem 2009; 284: 1765-1771.
24. Irizarry E, Newman KM, Gandhi RH, et al: Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993; 54: 571-574. (Pubitemid 23304756)
25. Wilson WR, Schwalbe EC, Jones JL, et al,: Matrix metalloproteinase 8 (neutrophil collagenase) in the pathogenesis of abdominal aortic aneurysm. Br J Surg 2005; 92: 828-833. (Pubitemid 40961399)
26. Kahari VM, Saarialho-Kere U,: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31: 34-45. (Pubitemid 29134483)
27. Mao D, Lee JK, VanVickle SJ, et al,: Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 1999; 261: 904-910. (Pubitemid 29408155)
28. Longo GM, Buda SJ, Fiotta N, et al: MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 2005; 137: 457-462.
29. Silence J, Lupu F, Collen D, et al,: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001; 21: 1440-1445. (Pubitemid 34219805)
30. Ikonomidis JS, Jones JA, Barbour JR, et al: Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg 2007; 133: 1028-1036. (Pubitemid 46435954)
31. Annabi B, Shedid D, Ghosn P, et al: Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J Vasc Surg 2002; 35: 539-546. (Pubitemid 44718601)
32. McMillan WD, Patterson BK, Keen RR, et al,: In situ localization and quantification of seventy-two-kilodalton type IV collagenase in aneurysmal, occlusive, and normal aorta. J Vasc Surg 1995; 22: 295-305.
33. McMillan WD, Patterson BK, Keen RR, et al,: In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol 1995; 15: 1139-1144.
34. Ikonomidis JS, Gibson WC, Butler JE, et al: Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation 2004; 110: II268-II273. (Pubitemid 39263734)
35. Xiong W, Knispel R, Mactaggart J, et al: Effects of tissue inhibitor of metalloproteinase 2 deficiency on aneurysm formation. J Vasc Surg 2006; 44: 1061-1066. (Pubitemid 46107227)
36. Schmoker JD, McPartland KJ, Fellinger EK, et al: Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007; 133: 155-161. (Pubitemid 46014197)
37. Crowther M, Goodall S, Jones JL, et al: Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg 2000; 32: 575-583.
38. Higashikata T, Yamagishi M, Sasaki H, et al: Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. Atherosclerosis 2004; 177: 353-360. (Pubitemid 39505268)
39. Tamarina NA, McMillan WD, Shively VP, et al,: Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122: 264-271; discussion 71-72.
40. Gadson PF, Jr., Dalton ML, Patterson E, et al: Differential response of mesoderm- and neural crest-derived smooth muscle to TGF-beta1: Regulation of c-myb and alpha1 (I) procollagen genes. Exp Cell Res 1997; 230: 169-180. (Pubitemid 27190637)
41. Dalton ML, Gadson PF, Jr., Wrenn RW, et al,: Homocysteine signal cascade: Production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-711. (Pubitemid 27318287)
42. Vaughan CJ, Casey M, He J, et al: Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation 2001; 103: 2469-2475. (Pubitemid 32493373)
43. Mc Kusick VA,. The cardiovascular aspects of Marfan's syndrome: A heritable disorder of connective tissue. Circulation 1955; 11: 321-342.
44. Pope FM, Burrows NP,: Ehlers-Danlos syndrome has varied molecular mechanisms. J Med Genet 1997; 34: 400-410. (Pubitemid 27226679)
45. Jones JA, Spinale FG, Ikonomidis JS,: Transforming growth factor-beta signaling in thoracic aortic aneurysm development: A paradox in pathogenesis. J Vasc Res 2009; 46: 119-137.
46. van Vlijmen-van Keulen CJ, Pals G, Rauwerda JA,: Familial abdominal aortic aneurysm: A systematic review of a genetic background. Eur J Vasc Endovasc Surg 2002; 24: 105-116. (Pubitemid 41079364)
47. Verloes A, Sakalihasan N, Koulischer L, et al: Aneurysms of the abdominal aorta: Familial and genetic aspects in three hundred thirteen pedigrees. J Vasc Surg 1995; 21: 646-655.
48. Verloes A, Sakalihasan N, Limet R, et al: Genetic aspects of abdominal aortic aneurysm. Ann N Y Acad Sci 1996; 800: 44-55. (Pubitemid 27028943)
49. Bergwerff M, Verberne ME, DeRuiter MC, et al: Neural crest cell contribution to the developing circulatory system: Implications for vascular morphology? Circ Res 1998; 82: 221-231. (Pubitemid 28080105)
50. Topouzis S, Majesky MW,. Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. Dev Biol 1996; 178: 430-445. (Pubitemid 26365049)
51. Thieszen SL, Dalton M, Gadson PF, et al: Embryonic lineage of vascular smooth muscle cells determines responses to collagen matrices and integrin receptor expression. Exp Cell Res 1996; 227: 135-145. (Pubitemid 26293424)
52. Lopez-Candales A, Holmes DR, Liao S, et al: Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997; 150: 993-1007. (Pubitemid 27106171)
53. Wolinsky H, Glagov S,: Comparison of abdominal and thoracic aortic medial structure in mammals. Deviation of man from the usual pattern. Circ Res 1969; 25: 677-686.
54. Wolinsky H,: Comparison of medial growth of human thoracic and abdominal aortas. Circ Res 1970; 27: 531-538.
55. Vorp DA, Raghavan ML, Muluk SC, et al: Wall strength and stiffness of aneurysmal and nonaneurysmal abdominal aorta. Ann N Y Acad Sci 1996; 800: 274-276. (Pubitemid 27028976)
56. Vorp DA, Schiro BJ, Ehrlich MP, et al: Effect of aneurysm on the tensile strength and biomechanical behavior of the ascending thoracic aorta. Ann Thorac Surg 2003; 75: 1210-1214. (Pubitemid 36399407)
57. Groenink M, Langerak SE, Vanbavel E, et al: The influence of aging and aortic stiffness on permanent dilation and breaking stress of the thoracic descending aorta. Cardiovasc Res 1999; 43: 471-480. (Pubitemid 29356385)
58. Mohan D, Melvin JW,: Failure properties of passive human aortic tissue. II-Biaxial tension tests. J Biomech 1983; 16: 31-44. (Pubitemid 13125812)
59. Grainger DJ,. TGF-beta and atherosclerosis in man. Cardiovasc Res 2007; 74: 213-222.
60. Strong JP, Malcom GT, McMahan CA, et al: Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727-735. (Pubitemid 29113454)
61. Taylor CA, Hughes TJ, Zarins CK,: Finite element modeling of three-dimensional pulsatile flow in the abdominal aorta: Relevance to atherosclerosis. Ann Biomed Eng 1998; 26: 975-987. (Pubitemid 128608930)
62. Ito S, Akutsu K, Tamori Y, et al: Differences in atherosclerotic profiles between patients with thoracic and abdominal aortic aneurysms. Am J Cardiol 2008; 101: 696-699. (Pubitemid 351625099)
63. LeMaire SA, Wang X, Wilks JA, et al: Matrix metalloproteinases in ascending aortic aneurysms: Bicuspid versus trileaflet aortic valves. J Surg Res 2005; 123: 40-48. (Pubitemid 40094643)
64. Sinha I, Bethi S, Cronin P, et al: A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: A role for matrix metalloproteinase 9 and 2. J Vasc Surg 2006; 43: 342-348. (Pubitemid 43221932)
65. McNulty M, Spiers P, McGovern E, et al: Aging is associated with increased matrix metalloproteinase-2 activity in the human aorta. Am J Hypertens 2005; 18: 504-509.
66. Barbour JR, Stroud RE, Lowry AS, et al: Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation. J Thorac Cardiovasc Surg 2006; 132: 788-795. (Pubitemid 44415882)
67. Patel MI, Melrose J, Ghosh P, et al: Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg 1996; 24: 82-92. (Pubitemid 26271958)
68. Thompson M, Cockerill G,: Matrix metalloproteinase-2: The forgotten enzyme in aneurysm pathogenesis. Ann N Y Acad Sci 2006; 1085: 170-174. (Pubitemid 47092005)
69. Davis V, Persidskaia R, Baca-Regen L, et al: Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998; 18: 1625-1633. (Pubitemid 28465416)
70. Freestone T, Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15: 1145-1151.
71. Newman KM, Ogata Y, Malon AM, et al: Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb 1994; 14: 1315-1320.
72. Newman KM, Jean-Claude J, Li H, et al: Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 1994; 20: 814-820. (Pubitemid 24365295)
73. Lesauskaite V, Epistolato MC, Castagnini M, et al,: Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology. Hum Pathol 2006; 37: 1076-1084. (Pubitemid 44080818)
74. Ailawadi G, Knipp BS, Lu G, et al: A nonintrinsic regional basis for increased infrarenal aortic MMP-9 expression and activity. J Vasc Surg 2003; 37: 1059-1066. (Pubitemid 36538932)
75. McMillan WD, Tamarina NA, Cipollone M, et al. Size matters: The relationship between MMP-9 expression and aortic diameter. Circulation 1997; 96: 2228-2232.
76. Freestone T, Turner RJ, Coady A, et al: Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15: 1145-1151.
77. Della Corte A, Quarto C, Bancone C, et al: Spatiotemporal patterns of smooth muscle cell changes in ascending aortic dilatation with bicuspid and tricuspid aortic valve stenosis: focus on cell-matrix signaling. J Thorac Cardiovasc Surg 2008; 135: 8-18, e1-2.
78. Ihling C, Szombathy T, Nampoothiri K, et al: Cystic medial degeneration of the aorta is associated with p53 accumulation, Bax upregulation, apoptotic cell death, and cell proliferation. Heart 1999; 82: 286-293. (Pubitemid 29429599)
79. Jones JA, Zavadzkas JA, Chang EI, et al: Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg 2010; 140: 653-659.
80. Taketani T, Imai Y, Morota T, et al: Altered patterns of gene expression specific to thoracic aortic aneurysms: microarray analysis of surgically resected specimens. Int Heart J 2005; 46: 265-277.
81. Forte A, Della Corte A, De Feo M, et al,: Role of myofibroblasts in vascular remodelling: focus on restenosis and aneurysm. Cardiovasc Res 2010; 88: 395-405.
82. Owens GK, Kumar MS, Wamhoff BR,: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801. (Pubitemid 38823766)
83. Kawai-Kowase K, Owens GK,: Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol 2007; 292: C59-C69. (Pubitemid 46127305)
84. Bunton TE, Biery NJ, Myers L, et al: Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001; 88: 37-43. (Pubitemid 32064080)
85. Lesauskaite V, Tanganelli P, Sassi C, et al: Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: Morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol 2001; 32: 1003-1011. (Pubitemid 32911325)
86. Knox JB, Sukhova GK, Whittemore AD, et al: Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997; 95: 205-212. (Pubitemid 27029964)
87. Fontaine V, Jacob MP, Houard X, et al: Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701-1710. (Pubitemid 35265529)
88. Petersen E, Gineitis A, Wagberg F, et al: Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 2000; 20: 457-461. (Pubitemid 32051132)
89. Baxter BT, Pearce WH, Waltke EA, et al: Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36: 1-12. (Pubitemid 41122881)
90. Takagi H, Matsui M, Umemoto T,: A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg 2010; 52: 1675-1681.
91. Rahman MN, Khan JA, Mazari FA, et al: A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal aortic aneurysm. Ann Vasc Surg 2011; 25: 32-38.
92. McMillan WD, Pearce WH,: Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999; 29: 122-127; discussion 7-9.
93. Elefteriades JA,: Editorial comment: Biomarkers for diagnosis in thoracic aortic disease. Cardiol Clin 2010; 28: 221-222.
94. Urbonavicius S, Urbonaviciene G, Honore B, et al: Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture-a systematic review. Eur J Vasc Endovasc Surg 2008; 36: 273-280; discussion 81-82.
95. Krzeski P, Buckland-Wright C, Balint G, et al: Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: A randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007; 9: R109.
96. Sangiorgi G, D'Averio R, Mauriello A, et al: Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001; 104: I288-I295. (Pubitemid 32884818)